Labcyte awarded 2nd Japanese patent for acoustic-based cell sorting system

NewsGuard 100/100 Score

Labcyte, the company that developed and commercialized the acoustic transfer of liquids today announced that the Japanese patent office has granted patent 4309131 that covers the design of an acoustic-based system that can sort cells based upon acoustic or other properties and then eject them specifically from a mixed population.

“This patent extends our intellectual property and expands our geographical positioning,” said Rich Ellson, Chief Technical Officer of Labcyte Inc. “This, our second Japanese patent, is part of our expansion throughout the Pacific Rim and it increases our portfolio to 48 patents across Japan, Europe and the U.S.”

“Until this patent, cells have been differentiated by optical methods,” said Ellson. “This patent doubles the detection methods available. Coupled with the acoustic detection of cells is the specific selection and transfer of cells acoustically. Cell transfer via acoustic methods is gentle and eliminates the effects of shear stress seen when cells are pushed through a narrow tube, as is done with pipette tips.”

“We expect that our technology as described in this patent will advance the science of cell sorting. It also continues to solidify Labcyte as an innovator in the arena of acoustic sciences,” said Ellson. “Our technology significantly improves the results of high-throughput screening in drug discovery as well as genomic research, including applications in PCR-based gene expression, RNAi studies and SNP analyses. Our platform technology is also being applied in other fields such as array formation, the microencapsulation of compounds, mono-dispersed particle production, proteomics research, the transfer of ultra-viscous materials, cell-based biology and imaging mass spectrometry.”

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Novel therapeutic approach identified for overcoming resistance in B-cell leukemia